Fly News Breaks for June 19, 2015
Jun 19, 2015 | 14:33 EDT
Leerink says that while the TKM-Ebola-Guinea field trial update is "clearly disappointing " for Tekmira's Ebola program, the main long-term driver for shares is still the company's hepatitis B program. The firm does not see any significant read-through to Tekmira's other programs and reiterates an Outperform rating on the stock. Leerink notes its $30 price target attributes only $1 to TKM-Ebola.
News For TKMR From the Last 2 Days
There are no results for your query TKMR